Find disease awareness content and relevant supporting materials
Full results of lecanemab phase III confirmatory Clarity AD study for early Alzheimer’s disease presented at Clinical Trials On Alzheimer’s Disease (Ctad) Conference
Eisai Co.,Ltd. and Biogen Inc. announced that the results from Eisai’s large global Phase III confirmatory Clarity AD clinical study of lecanemab (development code: BAN 2401), an investigational anti-amyloid beta (Abeta) protofibril antibody for the treatment of mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) and mild AD (collectively known as early AD) with confirmed presence of amyloid pathology in the brain, were presented at the 2022 Clinical Trials on Alzheimer’s Disease (CTAD) conference, in San Francisco, California and virtually
Anavax2 73 in Phase IIb/III study met primary endpoints for the treatment of mild cognitive impairment due to Alzheimer's disease.- Anavex Life Sciences
Anavex Life Sciences Corp. announced positive topline results from its Phase IIb/III ANAVEX2-73-AD-004 clinical trial of oral ANAVEX2 73 (blarcamesine) for the treatment of mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) and mild AD (collectively known as early AD).
Full findings from lecanemab confirmatory phase III trial (CLARITY AD) will be presented at Alzheimer's Disease conference
Eisai Co., Ltd. will present the efficacy, safety and biomarker findings from the company’s Phase III confirmatory Clarity AD clinical trial for lecanemab development code: BAN2401), an investigational anti-amyloid beta (A beta) protofibril antibody for the potential treatment of mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) and mild AD (collectively known as early AD) with confirmed presence of amyloid pathology in the brain, at the 15th Clinical Trials on Alzheimer’s Disease (CTAD) conference
Cannabinoids for the treatment of neuropsychiatric symptoms, pain and weight loss in dementia.
Purpose of review: Efficacious treatment for neuropsychiatric symptoms (NPS), pain and weight loss for dementia patients is desperately needed. This review presents an up-to-date look at the literature investigating the use of cannabinoid for these symptoms in dementia.
Phase III ACCORD trial of AXS 05 meets primary endpoint in Alzheimer’s Disease Agitation
Axsome Therapeutics announced that AXS 05 (bupropion + dextromethorphan), a novel, oral, investigational NMDA receptor antagonist with multimodal activity, met the primary and key secondary endpoints in the ACCORD (Assessing Clinical Outcomes in Alzheimer’s Disease Agitation) Phase III trial, by substantially and statistically significantly delaying the time to relapse and preventing relapse of agitation in patients with Alzheimer’s disease, as compared to placebo
FDA approval of Adalarity transdermal system for treatment of patients with Alzheimer's disease.
Corium, Inc., a commercial-stage biopharmaceutical company leading the development and commercialization of novel central nervous system (CNS) therapies, announced that the FDA has approved Corium’s Adalarity (donepezil transdermal system) as a treatment for patients with mild, moderate, or severe dementia of the Alzheimer’s type.
Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson's disease dementia.
Several studies have demonstrated clinical benefits of sustained cholinesterase inhibition with rivastigmine in Alzheimer's disease (AD) and Parkinson's disease dementia (PDD).
Donanemab data in first active comparator study,TRAILBLAZER-ALZ 4, in early symptomatic Alzheimer's disease
Eli Lilly and Company has announced that donanemab met all primary and secondary endpoints for the 6-month primary outco me analysis in the Phase III TRAILBLAZER-ALZ 4 study , providing the first active comparator data on amyloid plaque clearance in patients with early symptomatic Alzheimer's disease treated with amyloid-targeting therapies